PMID- 30851540
OWN - NLM
STAT- MEDLINE
DCOM- 20190617
LR  - 20200106
IS  - 2299-5684 (Electronic)
IS  - 1734-1140 (Linking)
VI  - 71
IP  - 2
DP  - 2019 Apr
TI  - A systematic review and meta-analysis of oxaceprol in the management of 
      osteoarthritis: An evidence from randomized parallel-group controlled trials.
PG  - 374-383
LID - S1734-1140(18)30545-0 [pii]
LID - 10.1016/j.pharep.2018.12.010 [doi]
AB  - Oxaceprol, a derivative of l-proline, is an established drug for managing 
      osteoarthritis (OA) with better safety profile than non-steroidal 
      anti-inflammatory drugs (NSAIDs). This systematic review and meta-analysis, 
      following Preferred Reporting Items for Systematic reviews and Meta-Analyses 
      (PRISMA) guidelines, evaluated the efficacy, safety and tolerability of oxaceprol 
      in OA. Electronic databases for published and grey (unpublished) literature were 
      searched to identify parallel-group randomized controlled trials (RCTs) 
      evaluating the impact of oxaceprol in patients with OA. Risk of bias was assessed 
      using the Cochrane collaboration's tool. A total of seven parallel-group RCTs 
      involving 1087 participants were included in the systematic review. 
      Meta-analysis, in Review Manager, demonstrated numerically greater/significant 
      improvements compared to active control [diclofenac/ibuprofen]/placebo in pain 
      and function of joint; similar improvement vs. active control in global treatment 
      efficacy; no difference/significant difference vs. active control/placebo in 
      NSAIDs as rescue medication. Treatment with oxaceprol showed numerically less 
      adverse events (AEs) than active control (diclofenac: risk ratio [RR], 0.71; 95% 
      confidence interval [CI], 0.45 to 1.11; p=0.14: ibuprofen: RR, 0.73; 95% CI, 0.30 
      to 1.78; p=0.49) and significantly fewer AEs compared to placebo (RR, 0.76; 95% 
      CI, 0.63 to 0.92; p=0.004). Given the nature of small-to-moderate sample size and 
      short duration of eligible studies, the available clinical evidence of oxaceprol 
      in the management of OA is modest - though looks promising. New and better RCTs 
      with larger sample size and longer follow-up are warranted to strengthen the use 
      of oxaceprol in clinical setting for managing OA.
CI  - Copyright (c) 2018 Institute of Pharmacology, Polish Academy of Sciences. Published 
      by Elsevier B.V. All rights reserved.
FAU - Durg, Sharanbasappa
AU  - Durg S
AD  - Real World Evidence, Molecular Connections (P) Ltd., Basavanagudi, Bengaluru, 
      India. Electronic address: sharanbasappa.d@molecularconnections.com.
FAU - Lobo, Melita
AU  - Lobo M
AD  - Real World Evidence, Molecular Connections (P) Ltd., Basavanagudi, Bengaluru, 
      India.
FAU - Venkatachalam, Lakshmi
AU  - Venkatachalam L
AD  - Real World Evidence, Molecular Connections (P) Ltd., Basavanagudi, Bengaluru, 
      India.
FAU - Rao, Guruprasad
AU  - Rao G
AD  - Real World Evidence, Molecular Connections (P) Ltd., Basavanagudi, Bengaluru, 
      India.
FAU - Bhate, Jignesh
AU  - Bhate J
AD  - Real World Evidence, Molecular Connections (P) Ltd., Basavanagudi, Bengaluru, 
      India.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20181226
PL  - Switzerland
TA  - Pharmacol Rep
JT  - Pharmacological reports : PR
JID - 101234999
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antirheumatic Agents)
RN  - 144O8QL0L1 (Diclofenac)
RN  - Q0XV76B96L (oxaceprol)
RN  - RMB44WO89X (Hydroxyproline)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects
MH  - Antirheumatic Agents/adverse effects/*therapeutic use
MH  - Diclofenac/administration & dosage/adverse effects
MH  - Humans
MH  - Hydroxyproline/adverse effects/*therapeutic use
MH  - Ibuprofen/administration & dosage/adverse effects
MH  - Osteoarthritis/*drug therapy/physiopathology
MH  - Randomized Controlled Trials as Topic
MH  - Sample Size
OTO - NOTNLM
OT  - Meta-analysis
OT  - Osteoarthritis
OT  - Oxaceprol
OT  - Safety
OT  - Systematic review
EDAT- 2019/03/10 06:00
MHDA- 2019/06/18 06:00
CRDT- 2019/03/10 06:00
PHST- 2018/09/06 00:00 [received]
PHST- 2018/11/10 00:00 [revised]
PHST- 2018/12/21 00:00 [accepted]
PHST- 2019/03/10 06:00 [pubmed]
PHST- 2019/06/18 06:00 [medline]
PHST- 2019/03/10 06:00 [entrez]
AID - S1734-1140(18)30545-0 [pii]
AID - 10.1016/j.pharep.2018.12.010 [doi]
PST - ppublish
SO  - Pharmacol Rep. 2019 Apr;71(2):374-383. doi: 10.1016/j.pharep.2018.12.010. Epub 
      2018 Dec 26.